Nuvectis Pharma Inc (NVCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $696.03M
Last updated: Nov 17, 2026 at 4:10 PM ET
Nuvectis Pharma Inc (NVCT) Statistics
Nuvectis Pharma (NVCT) has a market cap of $696.03M and an enterprise value of $555.32M. Its share count is up 29.70% from a year earlier. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 20.22% below the market cap, as cash exceeds debt.
| Market Cap | $696.03M |
|---|---|
| Enterprise Value | $555.32M |
| Latest price (Nov 17, 2026) | $19.20 |
Key Dates
The next earnings report is expected on Feb 9, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 9, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 4, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 218.94% over 52 weeks and trades 5.88% below its 50-day average.
| Beta (1Y) | 0.81 |
|---|---|
| 52-Week Change | +218.94% |
| 1-Month Change | +1.37% |
| 3-Month Change | -17.70% |
| 6-Month Change | +86.41% |
| Total Return (1Y) | +218.94% |
| Total Return (3Y CAGR) | +32.78% |
| Return vs SPY (1Y) | +205.80% |
| Max Drawdown (1Y) | -37.75% |
| Max Drawdown (3Y) | -58.91% |
| Sharpe Ratio (1Y) | 1.33 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $20.40 |
| 200-Day Average | $15.29 |
| 52-Week Range | $5.77 to $29.27 |
| RSI (14 Days) | 45.9 |
| Average Volume (20 Days) | 214.77K |
Financial Position
Current assets cover 9.92x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 9.92x |
|---|---|
| Quick Ratio | 9.92x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -39.84% and return on assets is -35.82% over the last 12 months.
| Return on Equity (ROE) | -39.84% |
|---|---|
| Return on Assets (ROA) | -35.82% |
Scores
NVCT has a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 3 of 9 |
|---|---|
| Piotroski Strength | Average |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$52.12M |
| Pretax Income | -$50.45M |
| Net Income | -$50.45M |
| Reported EPS (TTM) | -$1.89 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 89.92% of the $140.84M in total assets.
| Cash and Equivalents | $140.71M |
|---|---|
| Total Debt | $0 |
| Net Cash | $140.71M |
| Net Cash Per Share | $4.78 |
| Working Capital | $126.65M |
| Shareholder Equity | $126.65M |
| Book Value Per Share | $4.30 |
| Total Assets | $140.84M |
| Total Liabilities | $14.19M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$40.29M |
|---|---|
| FCF Per Share | -$1.23 |
| Share Repurchases | $9.49M |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | +9.78% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | +9.78% |
Dividends and Yields
NVCT does not pay a dividend.
| Buyback Yield | -25.70% |
|---|---|
| Shareholder Yield | -25.70% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About NVCT
What is NVCT's market cap?
Nuvectis Pharma has a market cap of $696.03M. Its enterprise value, which adds debt and subtracts cash, is $555.32M.
How many shares of NVCT are outstanding?
Nuvectis Pharma has 29.47M shares outstanding. The count is up 29.70% from a year earlier.
Does NVCT pay a dividend?
No. Nuvectis Pharma does not pay a dividend.
How much debt does NVCT have?
Nuvectis Pharma has $0 of total debt and $140.71M of cash and equivalents, a net cash position of $140.71M.
NVCT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors